7.50Open7.50Pre Close0 Volume6 Open Interest17.50Strike Price0.00Turnover6677.44%IV10.42%PremiumDec 20, 2024Expiry Date5.14Intrinsic Value100Multiplier-1DDays to Expiry2.36Extrinsic Value100Contract SizeAmericanOptions Type0.9475Delta0.0282Gamma4.40Leverage Ratio-85.0956Theta0.0000Rho4.17Eff Leverage0.0001Vega
Neurogene Stock Discussion
This Will continue to drive downward. And after you finally sell your position for a loss, they will buy back. Follow the money
📊⚡️📊
NEWS
Neurogene Announces Upcoming Presentation of Safety Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome at ASGCT Meeting
NEW YORK--(BUSINESS WIRE)-- Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that initial safety and tolerability data from its ongoing Phase 1/2 gene therapy clinical trial for Rett syndrome will be ...
No comment yet